Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand.

Suzi ClaflinJulie A CampbellRichard NormanDeborah F MasonTomas KalincikSteve Simpson-YapHelmut ButzkuevenWilliam M CarrollAndrew J PalmerC Leigh BlizzardIngrid van der MeiGlen J HensonBruce V Taylor

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)

HRQoL for people with MS in NZ was lower than comparable countries, including Australia. We suggest a comparison with other generic tools that may have improved sensitivity to mental health.

Keyphrases

multiple sclerosis
mental health
mass spectrometry
white matter
ms ms
public health
mental illness
cell therapy